Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Arbourmarkon Apr 08, 2021 8:37pm
189 Views
Post# 32964246

RE:Thank you

RE:Thank you

Great points Marky!


Marky1 wrote: Mugsy, Jimmy and Arbour and Forest...I agree with all said! I think that patience is what is needed here...Dan recently told me that he will look at the SP only in the summer...Makes perfect sense to me...I don't know about a Trillion as someone said here, but I definitely think that the company is worth North of 4B$ CDN...The science is indisputable, the need for our new  gentle NSAID is cried out by humanity, the business part,  whereby  Bayer and/ or Pfizer will lose a ton of revenue with the acceptance of Otenaproxesul....Dr. Haut with his amazing acquisitional knowledge is working for the good guys...Dr. Stauffer knows exactly how the FDA NSAIDs division works...knows the key people there, know how to write up a P3 test 
Thank You Dan for Getting us these remarkable men

Anyways...stay long folks...As Mugsy pointed out, Summer into Fall is when things will be heating up, not before, unless we get another "Nuance" deal...who saw that coming...no one
Take care and stay safe
JM

 

<< Previous
Bullboard Posts
Next >>